Skip to main content

Recombinant Human SCF GMP Protein, CF GMP

R&D Systems, part of Bio-Techne | Catalog # 255B-GMP

Animal-Free
R&D Systems, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
Loading...
255B-GMP-01M
255B-GMP-050

Key Product Details

Source

E. coli

Accession #

Conjugate

Unconjugated

Applications

Bioactivity

Product Specifications

Source

E. coli-derived human SCF/c-kit Ligand protein
Glu26-Ala189, with an N-terminal Met.
Produced using non-animal reagents in an animal-free laboratory.
Manufactured and tested under cGMP guidelines.

Purity

>97%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining. The result from mass spectrometry confirms the major peak corresponds to SCF/c-kit ligand. See the CofA for additional information.

Endotoxin Level

<0.10 EU per 1 μg of the protein by the LAL method.

N-terminal Sequence Analysis

Met-Glu26-Gly-Ile-(Cys)-Arg-Asn-Arg-Val-Thr

Predicted Molecular Mass

19 kDa

SDS-PAGE

17-18 kDa, reducing conditions

Activity

Measured in a cell proliferation assay using TF-1 human erythroleukemic cells. Kitamura, T. et al. (1989) J. Cell Physiol. 140:323.
The ED50 for this effect is 1‑5 ng/mL.

The specific activity of recombinant human SCF is >1.0 x 106 units/mg, which is calibrated against the human SCF reference standard (NIBSC code: 91/682).

Host Cell Protein

<0.1 ng per µg of protein when tested by ELISA.

Mycoplasma

Negative for Mycoplasma.

Host Cell DNA

<0.010 ng per µg of protein when tested by PCR.

Scientific Data Images for Recombinant Human SCF GMP Protein, CF

Recombinant Human SCF GMP Protein Bioactivity

Recombinant Human SCF GMP Protein Bioactivity

GMP-grade Recombinant Human SCF (Catalog # 255B-GMP) stimulates cell proliferation of the TF‑1 human erythroleukemic cell line. The ED50 for this effect is 1-5 ng/mL. Four independent lots were tested for activity and plotted on the same graph to show lot-to-lot consistency of GMP SCF.

Equivalent Bioactivity of GMP and Animal-Free grades of Recombinant Human SCF

Equivalent bioactivity of GMP (Catalog # 255B-GMP) and Animal-Free (AFL255) grades of Recombinant Human SCF as measured in cell proliferation assay (orange and green respectively).
Recombinant Human SCF GMP Protein SDS-PAGE

Recombinant Human SCF GMP Protein SDS-PAGE

2 μg/lane of GMP-grade Recombinant Human SCF (Catalog # 255B-GMP) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing R band at 18 kDa and NR band at 16 kDa, respectively.

Formulation, Preparation and Storage

255B-GMP
Formulation Lyophilized from a 0.2 μm filtered solution in PBS.
Reconstitution Reconstitute at 100 μg/mL in PBS.
Shipping The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • A minimum of 12 months when stored at ≤ -20 °C as supplied. Refer to lot specific COA for the Use by Date.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, ≤ -20 °C under sterile conditions after reconstitution.

Background: SCF/c-kit Ligand

Stem cell factor (SCF), also known as c-kit ligand (KL), mast cell growth factor (MGF), and steel factor (SLF), is a widely expressed 28‑40 kDa type I transmembrane glycoprotein (1). It promotes the survival, differentiation, and mobilization of multiple cell types including myeloid, erythroid, megakaryocytic, lymphoid, germ cell, and melanocyte progenitors (1‑7). SCF is a primary growth and activation factor for mast cells and eosinophils (8). Mature human SCF consists of a 189 amino acid (aa) extracellular domain (ECD), a 23 aa transmembrane segment, and a 36 aa cytoplasmic tail (9). The ECD shows both N‑linked and O-linked glycosylation (10). Proteolytic cleavage at two alternate sites in the extracellular juxtamembrane region releases a 25 kDa soluble molecule which is comparable to the only form produced by Steel-dickie mutant mice (11, 12). An alternately spliced isoform of human SCF lacks 28 aa that encompasses the primary proteolytic recognition site (13). Within the ECD of the long isoform (corresponding to this recombinant protein), human SCF shares 79%‑87% aa sequence identity with canine, feline, mouse, and rat SCF. Rat SCF is active on mouse and human cells, but human SCF is only weakly active on mouse cells (9). Noncovalent dimers of transmembrane or soluble SCF interact with the receptor tyrosine kinase SCF R/c‑kit to trigger receptor dimerization and signaling (14). SCF assists in the recovery of cardiac function following myocardial infarction by increasing the number of cardiomyocytes and vascular channels (15).

References

  1. Ashman, L.K. (1999) Int. J. Biochem. Cell Biol. 31:1037. 
  2. Sette, C. et al. (2000) Int. J. Dev. Biol. 44:599. 
  3. Yoshida, H. et al. (2001) J. Invest. Dermatol. Symp. Proc. 6:1. 
  4. Erlandsson, A. et al. (2004) Exp. Cell Res. 301:201. 
  5. Kapur, R. et al. (2002) Blood 100:1287. 
  6. Wang, C.-H. et al. (2007) Arterioscler. Thromb. Vasc. Biol. 27:540. 
  7. Bashamboo, A. et al. (2006) J. Cell Sci. 119:3039. 
  8. Reber, L. et al. (2006) Eur. J. Pharmacol. 533:327.
  9. Martin, F.H. et al. (1990) Cell 63:203.
  10. Arakawa, T. et al. (1991) J. Biol. Chem. 266:18942.
  11. Majumdar, M.K. et al. (1994) J. Biol. Chem. 269:1237.
  12. Brannan, C.I. et al. (1991) Proc. Natl. Acad. Sci. 88:4671.
  13. Anderson, D.M. et al. (1991) Cell Growth Differ. 2:373.
  14. Lemmon, M.A. et al. (1997) J. Biol. Chem. 272:6311.
  15. Kanellakis, P. et al. (2006) Cardiovasc. Res. 70:117.

Long Name

Stem Cell Factor

Alternate Names

c-kit Ligand, DCUA, DFNA69, FPH2, FPHH, KITLG, KL-1, MGF, SHEP7, SLF

Entrez Gene IDs

4254 (Human); 17311 (Mouse); 60427 (Rat); 403507 (Canine); 493937 (Feline)

Gene Symbol

KITLG

UniProt

Additional SCF/c-kit Ligand Products

Product Documents for Recombinant Human SCF GMP Protein, CF

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Note: Certificate of Analysis not available for kit components.

Manufacturing Specifications

GMP Proteins
R&D Systems, a Bio-Techne Brand's GMP proteins are produced according to relevant sections of the following documents: USP Chapter 1043, Ancillary Materials for Cell, Gene and Tissue-Engineered Products and Eu. Ph. 5.2.12, Raw Materials of Biological Origin for the Production of Cell-based and Gene Therapy Medicinal Products. 

R&D Systems' quality focus includes:

  • Manufactured and tested under an ISO 9001:2015 and ISO 13485:2016 certified quality system
  • Documented processes and QA control of documentation and process changes
  • Personnel training programs
  • Raw material testing and vendor qualification/monitoring
  • Fully validated equipment, processes and test methods
  • Equipment calibration schedules using a computerized calibration program
  • Facility maintenance, safety programs and pest control
  • Material review process for variances
  • Monitoring of stability over product shelf-life

R&D Systems strives to provide our customers with the analytical characteristics of each product so that customers may determine whether our products are appropriate for their research. The Certificate of Analysis provided contains the following lot specific information:

  • N-terminal amino acid analysis, SDS-PAGE analysis, mass spectrometry, and endotoxin level (as determined by LAL assay) performed on each bulk QC lot, not on individual bottlings of each QC lot
  • Post-bottling lot-specific bioassay results (compliance with an established range) and results of microbial testing according to USP
  • Host Cell Protein testing performed by ELISA
  • Mycoplasma testing by ribosomal RNA hybridization assay

Additional testing and documentation requested by the customer can be arranged at an additional cost. 

Production records and facilities are available for examination by appropriate personnel on-site at R&D Systems in Minneapolis, Minnesota USA.

R&D Systems sells GMP grade products for preclinical or clinical ex vivo use. They are not for in vivo use. Please read the following End User Terms prior to using this product.


Animal-Free Manufacturing Conditions
Our dedicated controlled-access animal-free laboratories ensure that at no point in production are the products exposed to potential contamination by animal components or byproducts. Every stage of manufacturing is conducted in compliance with R&D Systems' stringent Standard Operating Procedures (SOPs). Production and purification procedures use equipment and media that are confirmed animal-free.

Production

  • All molecular biology procedures use animal-free media and dedicated labware.
  • Dedicated fermentors are utilized in committed animal-free areas.

Purification

  • Protein purification columns are animal-free.
  • Bulk proteins are filtered using animal-free filters.
  • Purified proteins are stored in animal-free containers in a dedicated cold storage room.

    Quality Assurance

    • Low Endotoxin Level.
    • No impairment of biological activity.
    • High quality product obtained under stringent conditions.
    Please read our complete Animal-Free Statement

    Product Specific Notices for Recombinant Human SCF GMP Protein, CF

    END USER TERMS OF USE OF PRODUCT

    The following terms are offered to you upon your acceptance of these End User Terms of Use of Product. By using this product, you indicate your acknowledgment and agreement to these End User Terms of Use of Product. If you do not agree to be bound by and comply with all of the provisions of these End User Terms of Use of Product, you should contact your supplier of the product and make arrangements to return the product.

    We suggest you print and retain a copy of these End User Terms of Use of Product for your records.

    The End User is aware that R&D Systems, Inc. sells GMP products for preclinical or clinical ex vivo use and not for in vivo use. The End User further agrees, as a condition of the sale of R&D Systems' GMP products that: a) the End User will not use this GMP Product in any procedure wherein the product may be directly or indirectly administered to humans, unless the End User has obtained, or prior to their use will have obtained, an Investigational New Drug (IND) exemption from the FDA and will use the product only in accordance with the protocols of such IND and of the Institutional Review Board overseeing the proposed research, or b) the End User will use the products outside of the United States in accordance with the protocols of research approved by the Institutional Review Board or authorized ethics committee and regulatory agencies to which the End User is subject to in their territory.

    R&D Systems, Inc. has the right, at its sole discretion, to modify, add or remove any terms or conditions of these End User Terms of Use without notice or liability to you. Any changes to these End User Terms of Use are effective immediately following the printing of such changes on this product insert. The most recent version of these End User Terms of Use of Product may be found at: RnDSystems.com/Legal.

    You agree to review these End User Terms of Use of Product to ensure any subsequent use by you of R&D Systems' GMP Products following changes to these End User Terms of Use of Product constitutes your acceptance of all such changes.

     

    TERMS AND CONDITIONS

    The following limitation applies to R&D Systems' warranty and liability for damages: All products are warranted to meet R&D Systems' published specifications when used under normal laboratory conditions.

    R&D SYSTEMS DOES NOT MAKE ANY OTHER WARRANTY OR REPRESENTATION WHATSOEVER, WHETHER EXPRESS OR IMPLIED, WITH RESPECT TO ITS PRODUCTS. IN PARTICULAR, R&D SYSTEMS DOES NOT MAKE ANY WARRANTY OF SUITABILITY, NONINFRINGEMENT, MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE.

    NOTWITHSTANDING ANY OTHER PROVISIONS OF THESE TERMS AND/OR ANY OTHER AGREEMENT BETWEEN R&D SYSTEMS AND PURCHASER FOR THE PURCHASE OF THE PRODUCTS, R&D SYSTEMS' TOTAL LIABILITY TO PURCHASER ARISING FROM OR IN RELATION TO THESE TERMS, AN AGREEMENT BETWEEN THE PARTIES OR THE PRODUCTS, WHETHER ARISING IN CONTRACT, TORT OR OTHERWISE SHALL BE LIMITED TO THE TOTAL AMOUNT PAID BY PURCHASER TO R&D SYSTEMS FOR THE APPLICABLE PRODUCTS. IN NO EVENT WILL R&D SYSTEMS BE LIABLE FOR THE COST OF PROCUREMENT OF SUBSTITUTE GOODS.

    Full details of R&D Systems' Terms and Conditions of Sale can be found online at: RnDSystems.com/Legal.

    For preclinical, or clinical ex vivo use

    Loading...
    Loading...
    Loading...